Neoadjuvant chemotherapy for hypopharyngeal carcinoma

Masato Fujii, Tatsuo Matsunaga, Koichi Tsunoda, Kunio Mizutari, Ryoiti Fujii, Kanako Masuda, Satoko Kimura, Toshiki Tomita, Hiroyuki Ozawa, Takekatsu Fujimine

研究成果: Article

抜粋

The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.

元の言語English
ページ(範囲)363-368
ページ数6
ジャーナルToukeibu Gan
31
発行部数3
DOI
出版物ステータスPublished - 2005 1 1

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Oncology

フィンガープリント Neoadjuvant chemotherapy for hypopharyngeal carcinoma' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Fujii, M., Matsunaga, T., Tsunoda, K., Mizutari, K., Fujii, R., Masuda, K., Kimura, S., Tomita, T., Ozawa, H., & Fujimine, T. (2005). Neoadjuvant chemotherapy for hypopharyngeal carcinoma. Toukeibu Gan, 31(3), 363-368. https://doi.org/10.5981/jjhnc.31.363